Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Crinetics Pharmaceuticals (CRNX) EPS (Weighted Average and Diluted) (2020 - 2025)

Crinetics Pharmaceuticals has reported EPS (Weighted Average and Diluted) over the past 6 years, most recently at -$1.29 for Q4 2025.

  • Quarterly results put EPS (Weighted Average and Diluted) at -$1.29 for Q4 2025, down 48.28% from a year ago — trailing twelve months through Dec 2025 was -$4.94 (down 33.51% YoY), and the annual figure for FY2025 was -$4.95, down 34.15%.
  • EPS (Weighted Average and Diluted) for Q4 2025 was -$1.29 at Crinetics Pharmaceuticals, up from -$1.38 in the prior quarter.
  • Over the last five years, EPS (Weighted Average and Diluted) for CRNX hit a ceiling of -$0.7 in Q2 2021 and a floor of -$1.38 in Q3 2025.
  • Median EPS (Weighted Average and Diluted) over the past 5 years was -$0.88 (2023), compared with a mean of -$0.93.
  • Biggest five-year swings in EPS (Weighted Average and Diluted): increased 4.95% in 2024 and later crashed 48.28% in 2025.
  • Crinetics Pharmaceuticals' EPS (Weighted Average and Diluted) stood at -$0.8 in 2021, then dropped by 3.55% to -$0.83 in 2022, then dropped by 6.02% to -$0.88 in 2023, then increased by 1.14% to -$0.87 in 2024, then crashed by 48.28% to -$1.29 in 2025.
  • The last three reported values for EPS (Weighted Average and Diluted) were -$1.29 (Q4 2025), -$1.38 (Q3 2025), and -$1.23 (Q2 2025) per Business Quant data.